6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder

PHASE2TerminatedINTERVENTIONAL
Enrollment

131

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Major Depressive Disorder
Interventions
DRUG

AZD2066

18 mg once daily

DRUG

Placebo

DRUG

Duloxetine

60 mg once daily

Trial Locations (13)

Unknown

Research Site, Garden Grove

Research Site, San Diego

Research Site, Jacksonville

Research Site, Atlanta

Research Site, Rockville

Research Site, Boston

Research Site, Cedarhurst

Research Site, Rochester

Research Site, Portland

Research Site, Memphis

Research Site, Friendswood

Research Site, Bellevue

Research Site, Seattle

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY